{"id":18395,"date":"2026-02-25T16:08:08","date_gmt":"2026-02-25T16:08:08","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/18395\/"},"modified":"2026-02-25T16:08:08","modified_gmt":"2026-02-25T16:08:08","slug":"novartis-to-build-new-radioligand-therapy-site-in-texas-to-deliver-next-generation-treatments","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/18395\/","title":{"rendered":"Novartis to build new radioligand therapy site in Texas to deliver next-generation treatments"},"content":{"rendered":"

\"Novartis<\/a><\/p>\n

Today Novartis announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This\u00a0purpose-built\u00a0RLT\u00a0site\u00a0will be the\u00a0company\u2019s fifth in the US and\u00a0first manufacturing facility\u00a0in Texas,\u00a0and\u00a0marks further progress in the company\u2019s\u00a0$23 billion US investment<\/a>.<\/p>\n

The Denton site is expected to create new Novartis jobs in bioengineering, advanced manufacturing, quality and operations, supporting economic growth in Denton and surrounding communities. Construction is scheduled to begin this year, with the site expected to become fully operational in 2028.\u00a0<\/p>\n

\u201cRLT has the potential to revolutionize cancer care,\u201d said Vas Narasimhan, CEO of Novartis. \u201cThe addition of our fifth RLT manufacturing site in the US strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.\u201d\u00a0<\/p>\n

\u201cTexas is a leading biotech hub and home to groundbreaking advancements in medicine,\u201d said Governor Greg Abbott. \u201cThis significant investment by Novartis in Denton will establish their first manufacturing facility in Texas for cancer therapies and create good-paying jobs in bioengineering, advanced manufacturing, and more. Working together with innovative global leaders, we will continue to strengthen critical supply chains to help speed next-generation treatments to patients across Texas and the US.\u201d\u00a0<\/p>\n

The Texas site will join a comprehensive Novartis RLT manufacturing network, with existing US sites in New Jersey, Indiana and California and a recently announced site to be constructed in Florida \u2014 providing unmatched RLT capacity from coast to coast. The manufacturing network has a longstanding record of enabling >99% of doses to be administered on the planned day. Each dose of RLT is custom-made and time-sensitive, making proximity to patients and treatment centers critical.<\/p>\n

Novartis and radioligand therapy (RLT)
Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells anywhere in the body.\u00a0\u00a0<\/p>\n

Novartis is actively investigating the application of RLTs across cancer types and settings, with one of the deepest and most advanced pipelines in the industry, with trials in prostate cancer, breast, colon, lung, brain, pancreatic and other cancers. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites around the world.\u00a0<\/p>\n

Source: Novartis<\/p>\n","protected":false},"excerpt":{"rendered":"Today Novartis announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This\u00a0purpose-built\u00a0RLT\u00a0site\u00a0will…\n","protected":false},"author":2,"featured_media":18396,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[2112,206,265,8167,12566],"class_list":["post-18395","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-cancer","tag-novartis","tag-oncology","tag-patient-access","tag-radioligand"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/18395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=18395"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/18395\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18396"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=18395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=18395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=18395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}